WILMINGTON, Del. & PARSIPPANY, N.J.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) and The Medicines Company (NASDAQ: MDCO) announced today a global collaboration for acute ischemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca’s oral antiplatelet medicine BRILINTA® (ticagrelor) tablets. Under the terms of the co-promotion agreement, The Medicines Company sales force will begin supporting BRILINTA in May 2012. This will complement the AstraZeneca sales team’s promotion of BRILINTA to US hospital customers and practitioners whose patients with acute coronary syndrome (ACS) may benefit from this important therapy.
